Jefferies Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Jefferies Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-24	Closed	-$2.33K	–	2237
2021 Q2	$2.33K	Buy	+24	New	+$1.95K	﹤0.01%	1610
2021 Q1	–	Sell	-18,582	Closed	-$1.59M	–	2185
2020 Q4	$1.59M	Buy	18,582 +10,319	+125%	+$874K	0.01%	794
2020 Q3	$537K	Sell	8,263 -3,653	-31%	-$239K	0.01%	965
2020 Q2	$871	Sell	11,916 -8,731	-42%	-$465K	0.01%	796
2020 Q1	$703K	Buy	20,647 +1,674	+9%	+$76.5K	0.01%	1173
2019 Q4	$1.03M	Sell	18,973 -24,937	-57%	-$1.23M	0.01%	1442
2019 Q3	$1.83M	Sell	43,910 -18,282	-29%	-$772K	0.01%	1140
2019 Q2	$2.72M	Sell	62,192 -67,363	-52%	-$3.8M	0.02%	770
2019 Q1	$6.67M	Buy	+129,555	New	+$5.6M	0.05%	335

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group's BHVN Position: Q3 2021 in Review

Jefferies Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2021, closing a stake of 24 shares — an estimated $2.33K sold.

Jefferies Group first reported a position in BHVN in Q1 2019 and held it in 9 quarters. The position peaked at $6.67M in Q1 2019. 249 funds tracked by Wall St. Rank hold BHVN as of Q3 2021.

Jefferies Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2021 after selling out during the quarter.
Jefferies Group sold 24 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2021, an estimated $2.33K.
Jefferies Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 9 quarters.
Jefferies Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.67M in Q1 2019.
249 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2021.

Based on Jefferies Group's 13F filing for Q3 2021, filed 15 Nov 2021.